Library note: Fitzpatrick's Dermatology and Rooks/Dermatology 2-Volume Set 5e (Bolivnia) are available in the textbook library and were read in full. Wolverton's Comprehensive Dermatologic Drug Therapy and the IADVL Textbook of Dermatology are not indexed in the library. IADVL/Indian recommendations below are drawn from the ERAISE ACNE Indian expert consensus (Dermatology & Therapy 2026) and the IAA/IADVL acne consensus document (IJDVL 2009).

Isotretinoin - Comprehensive Main Points

1. Structure and Pharmacology

• Half-life: ~20 hours (vs ~1 hour for all-trans-retinoic acid)

• 99% protein-bound in plasma, mainly to albumin

• No storage in liver or adipose tissue (contrast to vitamin A and etretinate - important pharmacokinetic advantage)
• First-pass hepatic metabolism + enterohepatic recycling
• Major metabolite: 4-oxo-isotretinoin (oxidation; retains sebosuppressive activity)
• Excreted in urine and feces
• After discontinuation: physiologic concentrations reached within 2 weeks - hence 1 month post-therapy contraception is adequate
• Absorption enhanced by fatty meal (standard formulation); lidose/Absorica can be taken without food

2. Mechanism of Action

• Sebum suppression lasts >1 year in some patients; returns to normal in 2-4 months in most
• Long-term remission mechanism after sebum normalization: remains incompletely understood

3. Indications

Approved/Primary:

• Severe recalcitrant nodular/nodulocystic acne unresponsive to other therapy including oral antibiotics

Extended Indications (Fitzpatrick, Rooks, IADVL/Indian consensus):

• Significant acne unresponsive to standard therapy (oral antibiotics + topical retinoid)
• Moderate acne with scarring or rapid relapse
• Acne causing significant psychosocial burden (qualifies as "severe" - AAD 2024)
• Gram-negative folliculitis
• Pyoderma faciale (rosacea fulminans)
• Acne fulminans (requires systemic corticosteroid pretreatment)
• Hidradenitis suppurativa (limited efficacy)
• Dissecting cellulitis of scalp
• Acne with solid facial edema (Morbihan disease)
• Eosinophilic pustular folliculitis (Ofuji disease)
• Pityriasis rubra pilaris
• Darier disease
• Keratodermas, various ichthyoses
• Confluent and reticulate papillomatosis
• Photoaging (low-dose, off-label; mixed evidence)
• Chemoprevention: xeroderma pigmentosum, basal cell nevus syndrome, organ transplant recipients

• Endorsed for: severe conglobate, nodulocystic, severe papulopustular acne
• Risk-based early use in select moderate cases after first-line failure - to prevent scarring and PIH
• Low-dose regimens are acceptable for moderate or persistent mild acne

4. Dosing

Standard Acne Dosing:

• Allow at least 2-3 months between courses
• ~10% (Fitzpatrick) to ~33% (Rooks) require a second course
• Predictors of relapse/need for repeat: age <16-17 years, male sex, short course, low cumulative dose, closed comedonal/microcystic acne
• PCOS/hormonal acne: poor responders; exclude hyperandrogenemia in refractory/relapsing cases

5. Adverse Effects

A. Mucocutaneous (Dose-Dependent, Most Common)

B. Ophthalmic

• Xerophthalmia, blepharoconjunctivitis - common
• Reduced night vision / night blindness
• Keratitis, photophobia, corneal ulceration - rare
• Corneal opacities, optic neuritis - reported

C. Musculoskeletal

• Myalgias - most common musculoskeletal symptom (15%); check CPK in severe cases (rhabdomyolysis risk)
• Arthralgias
• Hyperostosis - more likely with high-dose/long-term use (keratinization disorders); less concern for standard 5-month acne courses
• Bone density: single acne course does not significantly affect; repeated/chronic courses may cause osteopenia, fractures

D. Metabolic / Laboratory

• Risk of eruptive xanthomas and acute hemorrhagic pancreatitis at very high triglyceride levels

E. Neuropsychiatric

• Pseudotumor cerebri (benign intracranial hypertension): headache, nausea, visual changes, papilledema - rare but serious
  • Do not co-prescribe with tetracyclines (additive risk)
  • Requires urgent neurological evaluation if suspected
• Depression, suicidal ideation, psychosis: relationship controversial; meta-analysis of 9 studies found NO increased incidence of depression vs. untreated acne patients; biological plausibility exists (CNS penetration in animals; case reports); screen all patients and warn

F. Gastrointestinal

• Nausea, anorexia, abdominal pain, diarrhea
• IBD (inflammatory bowel disease): case reports and one study showing association with ulcerative colitis; causal relationship NOT established (Rooks 5e)

G. Teratogenicity (Category X - Most Serious Adverse Effect)

• Not mutagenic - acts on organogenesis
• Peak risk: ~3rd-4th week of gestation (neural crest cell toxicity)
• No risk from male partner taking isotretinoin (not mutagenic; no abnormalities in sperm)

• CNS: hydrocephalus, microcephaly, cortical agenesis, cerebellar hypoplasia, mental retardation
• Cardiovascular: conotruncal + aortic arch defects (Tetralogy of Fallot, transposition of great vessels, truncus arteriosus, interrupted aortic arch)
• Craniofacial: microtia, anotia, atresia of ear canal, microphthalmia, cleft palate, micrognathia
• 3rd and 4th pharyngeal pouches: thymic/parathyroid hypoplasia
• Other: limb anomalies, anal/vaginal atresia

6. Contraindications

• Pregnancy (absolute) - Category X
• Hypersensitivity to isotretinoin or parabens (vehicle)
• Concurrent tetracyclines - pseudotumor cerebri risk
• Severe hepatic insufficiency
• Hypervitaminosis A
• Uncontrolled hyperlipidemia

7. Key Drug Interactions

8. Laboratory Monitoring

Fitzpatrick's:

• Baseline: CBC, LFTs, fasting lipid panel
• Repeat at 4 and 8 weeks
• If normal at 8 weeks + no risk factors: no further routine testing needed
• CBC monitoring: not necessary in otherwise healthy patients

Rooks:

• Baseline fasting lipids + LFTs
• Monthly for first 2 months; then every 3 months if stable
• Low-risk adolescents/young adults: baseline + 2 months; if normal, may reduce frequency
• Triglycerides >800 mg/dL: discontinue therapy

IADVL/Indian (ERAISE ACNE 2025):

• Laboratory monitoring especially in patients with metabolic risk factors
• No consensus on universal frequency; risk-stratified approach recommended

9. Pregnancy Prevention Program

iPLEDGE (USA - mandatory):

• Physicians and patients must register
• Two negative pregnancy tests before starting
• Two forms of effective contraception: start 1 month before, continue during, and for 1 month after
• Monthly pregnancy tests during therapy
• No more than 1 month's supply dispensed at a time
• No blood donation during treatment or for 1 month after

Indian practice (IADVL/ERAISE):

• No formal national registry comparable to iPLEDGE
• Two forms of contraception recommended
• Monthly pregnancy tests
• Mandatory counseling with documented understanding

10. Special Situations

Acne Fulminans / Severe Initial Flare:

• Start isotretinoin at very low dose (0.1 mg/kg/day)
• Pre-treat with prednisone 0.5-1 mg/kg/day for 2-4 weeks before starting isotretinoin
• Continue corticosteroids concurrently during initial weeks, taper slowly
• Isotretinoin-induced acne fulminans: rare; more common in young adolescent males

Isotretinoin and Surgery/Procedures:

• Traditional: avoid elective dermabrasion/surgery for 6-12 months after course
• Systematic review (JAMA Dermatology 2017): individualize timing based on procedure type

Pediatric (<16-17 years):

• Higher relapse rates; may need higher cumulative doses

Photosensitivity:

• Advise sunscreen use throughout treatment

11. High-Yield Points for Exams (IADVL/Dermatology Board)

1. Only retinoid with significant sebum suppression - mechanism is sebocyte apoptosis, NOT RAR/RXR
2. Targets all 4 pathogenic factors of acne
3. Cumulative dose 120-150 mg/kg is the target to minimize relapse
4. Cheilitis in virtually all patients - marker of adequate dosing; reassure
5. NEVER combine with tetracyclines - pseudotumor cerebri
6. Contraception: 1 month before + during + 1 month after; only 1 month washout needed (clears in 2 weeks)
7. Not mutagenic - no teratogenic risk from male patients
8. Triglycerides >800 mg/dL: stop isotretinoin
9. Depression: meta-analyses show no increased risk vs. untreated acne; still screen all patients
10. IBD: not causally proven
11. Lidose/Absorica: food-independent absorption
12. Acne fulminans on isotretinoin: start low dose + steroid cover
13. PCOS/hormonal acne: poor response; investigate before repeat courses
14. Low-dose regimen (20 mg/day): acceptable for moderate acne in India; use adequate cumulative dose

• Fitzpatrick's Dermatology Vols 1-2, pp.1437-1438 (Acne Ch.), pp.3428-3445 (Retinoids Ch. 185)
• Rooks/Dermatology 2-Volume Set 5e, pp.730-732 (Acne Ch.36), pp.2665-2678 (Retinoids Ch.126)
• ERAISE ACNE: Indian expert consensus on isotretinoin, Dermatology & Therapy 2026
• Kubba R et al. (IADVL/IAA). Acne in India: guidelines for management. IJDVL 2009;75:1-62